Journal
MEDICINAL RESEARCH REVIEWS
Volume 29, Issue 2, Pages 272-294Publisher
WILEY
DOI: 10.1002/med.20130
Keywords
dopamine; dopamine receptor; benzazepine; dihydrexidine; Parkinson's disease
Categories
Funding
- Chinese National Science Foundation [306725 17]
- Shanghai Commission of Science and Technology [07pj14104]
- Ministry of Science and Technology [2007AA02z163]
- Shanghai Institute of Materia Medica
Ask authors/readers for more resources
The dopamine (DA) D-1 receptor is the most highly expressed DA receptor subtype among the DA receptor family. Although the first DA D-1 receptor selective ligand SCH-23390 (1) was introduced more than two decades ago, clinically useful D-1 receptor selective ligands are rare. A renewed interest was ignited in the early 1990s by Nichols and Mailman who developed dihydrexidine (27a), the first high affinity full efficacy agonist for the D-1 receptor. Since then, a number of D-1 receptor agonists with full intrinsic activity, including A-86929 (31a), dinapsoline (32a), dinoxyline (34a), and doxanthrine (35a) were identified. These compounds all contain a conformationally rigid structure. However, the fate of such ligands for clinical use as treatments of Parkinson's disease and other related CNS disorders is not optimistic since the clinical trial with dihydrexidine (27a) was not successful. Further investigations on other compounds which are currently in the discovery stage will be crucial for determining the future of the D-1 receptor agonists. (C) 2008 Wiley Periodicals, Inc. Med Res Rev, 29, No. 2, 272-294, 2009
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available